SUBSCRIBE
SUBSCRIBE

Phase II

Policy
Biopharma Update on the Novel Coronavirus: May 7
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 7, 2020.
May 7, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: May 6
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 6, 2020.
May 6, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Drug Development
Sanofi and Regeneron’s Libtayo Shows Benefit in Basal Cell Carcinoma
Sanofi and Regeneron are focusing on basal cell carcinoma treatment and their drug Libtayo is showing good results. The companies expect to make regulatory submissions this year.
May 5, 2020
 · 
3 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: May 5
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 5, 2020.
May 5, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: May 4
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 4, 2020.
May 4, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Drug Development
Biotech Professionals Express Fears…and Hope, During Pandemic
While the biopharmaceutical industry is working frantically to develop the tests, vaccines and therapeutics to combat COVID-19, the people doing the work are pushing their fears to one side. But, when asked, they admit to concerns. Not suprisingly, they mirror the fears shared by much of the world.
May 1, 2020
 · 
5 min read
 · 
Gail Dutton
Bio NC
Clinical Catch-Up: April 27-May 1
There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.
May 1, 2020
 · 
11 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: May 1
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 1, 2020.
May 1, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: April 30
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 30, 2020.
April 30, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: April 29
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 29, 2020.
April 29, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Load More
PRESS RELEASES
Press Releases
D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002
January 19, 2026
 · 
3 min read
Press Releases
Nouscom Highlights Potential of NOUS-209 to Intercept Cancer in Lynch Syndrome Carriers in Seminal Nature Medicine Publication
January 16, 2026
 · 
8 min read
Press Releases
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)
January 16, 2026
 · 
7 min read
Press Releases
HMNC Brain Health Presented Positive Phase 2b Data at American College of Neuropsychopharmacology Annual Meeting
January 16, 2026
 · 
3 min read
Press Releases
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
January 16, 2026
 · 
7 min read
Press Releases
AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Clinical Trial of AAVB-081 for Usher Syndrome Type B-associated Retinitis Pigmentosa
January 16, 2026
 · 
4 min read
Press Releases
Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral ‘XAFTY’ Following 2026 Biotech Showcase Consensus
January 15, 2026
 · 
3 min read
Press Releases
Gradalis’ Vigil® Demonstrates Significant Survival Benefit in cTMB-H / HRP Ovarian Cancer Patients; Phase 2b VITAL Trial Analysis Published in JCO – Precision Oncology
January 15, 2026
 · 
8 min read
Press Releases
Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate
January 14, 2026
 · 
4 min read
Press Releases
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101
January 14, 2026
 · 
10 min read
Press Releases
Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2
January 14, 2026
 · 
4 min read
Press Releases
Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS
January 13, 2026
 · 
4 min read
Press Releases
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
January 13, 2026
 · 
2 min read
Press Releases
Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research in Idiopathic Pulmonary Fibrosis
January 13, 2026
 · 
3 min read
Press Releases
Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting a Durable Complete Response Beyond One Year and a 66.7% ORR in Advanced GC/GEJ
January 13, 2026
 · 
5 min read
Press Releases
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
January 13, 2026
 · 
4 min read
Press Releases
Insilico Medicine Completes First Patient First Dose in BETHESDA: A Phase II Trial for Garutadustat (ISM5411), the Gut-restricted AI-driven PHD Inhibitor for the Treatment of Inflammatory Bowel Disease
January 13, 2026
 · 
4 min read
Press Releases
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026
January 13, 2026
 · 
7 min read
Press Releases
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
January 13, 2026
 · 
7 min read
Press Releases
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026
January 13, 2026
 · 
9 min read
Load More